Request PDF on ResearchGate | On Feb 1, , Hugo Donato and others published Tratamiento con eritropoyetina humana recombinante. Se demostró que el tratamiento con eritropoyetina humana recombinante (EPO rHu) en pacientes en diálisis es altamente efectivo en cuanto a la corrección de. Eritropoyetina humana recombinante para la anemia de la insuficiencia renal crónica en pacientes en prediálisis. This is not the most recent version of this.
|Published (Last):||5 September 2004|
|PDF File Size:||17.23 Mb|
|ePub File Size:||18.10 Mb|
|Price:||Free* [*Free Regsitration Required]|
Among the remaining 96 patients 40 BEN and 56 others who met inclusion criteria, 10 with BEN and 14 with other kidney diseases were selected using systematic sampling i. Subscribe to receive email notifications whenever new articles are published. A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection. However, several authors reported no significant differences between anemia in BEN and other kidney diseases.
As the main organs involved in Epo elimination are the kidneys and bone marrow and both kidney function and bone marrow cellularity decrease with age, the authors suggested that age and creatinine influence Rcombinante elimination.
Eur J Haematol ; Statistical analysis The results were expressed as mean values with standard deviations. Pharmacokinetic analysis of beta-erythropoietin detected a significantly longer elimination half-life in BEN than in non BEN patients.
Renal function, protein excretion and pathology of Balkan endemic nephropathy. The values of C max and t max are comparable to those found by other authors, taking into account the above mentioned differences in methodology. The present study was initiated from earlier data involving BEN and 94 non-BEN patients, which showed that significantly higher beta-Epo doses for reaching and maintaining target hemoglobin level were necessary in BEN than in non-BEN patients.
Eritropoyetina Humana Recombinante –
Results of laboratory analyses in the examined individuals are given in Table 2. This finding needs to be confirmed in a well-controlled study with a larger sample size.
These differences remained eritropoyetima after adjustment for patient characteristics age, sex, hemodialysis duration, ferritin, PTH and ACEI use. The presented profiles show greater inter-individual variability in Yumana concentration but a faster decrease of Epo level during the elimination phase in non-BEN than in BEN patients.
After beta-Epo administration plasma Epo slowly increased and C max was achieved after J Pharm Sci ; Erythropoietin resistance and survival in non-dialysis patients with stage chronic kidney disease and heart disease.
Der Mechanismus der Anaemie bie der endemische Nephropathie. Endemic nephropathy in Yugoslavia. This material is provided for educational purposes only and is not ertropoyetina for medical advice, diagnosis or treatment. Br J Clin Pharmacol ; J Am Soc Nephrol ; Blood samples were centrifuged for 10 min and plasma stored frozen until analysis.
J Clin Pharmacol ; In addition, iron status was assessed and supplementary iron given according to the same guidelines. Comparison of the pharmacokinetics of beta-erythropoietin given subcutaneously to hemodialysis patients with BEN or other kidney diseases non-BEN. Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers.
The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. By clicking Subscribe, I agree to the Drugs. Main characteristics of the patients ACEI: The group with other kidney diseases consisted of 8 patients with glomerulonephritis, 3 with hypertensive nephropathy, 2 with reflux nephropathy and 1 with polycystic kidney disease.
Eritropoyetina Humana Recombinante Delta
We cannot confirm the completeness, accuracy and currency of the content. Available for Android and iOS devices.
However, the influence of ESA pharmacokinetics on hematopoietic response has not been sufficiently investigated. A total of 24 subjects was selected decombinante the population of hemodialysis patients according to the following inclusion criteria: Results of laboratory analyses in examined patients CRP: The aim of this study was to compare the pharmacokinetics of beta-erythropoietin beta-Epo given subcutaneously to BEN patients and patients with other kidney diseases non-BEN and to evaluate the factors influencing beta-Epo kinetics.
The main limitation of our study was the small number of patients in each group, and they were not matched in age. To view content sources and attributions, please refer to our editorial policy. Faculty of Pharmacy, University of Belgrade, Serbia. J Am Soc Nephrol ;5: The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.
These findings need to be confirmed in a well-controlled study with a larger sample size in order to establish population pharmacokinetics of beta-Epo in BEN patients, to evaluate the effects of physiopathological factors on the disposition kinetics of beta-Epo and to find potential predictive factors for dosage individualization. Therefore, not only the humaba by itself, but also the process of elimination and interaction directly with the Epo receptor on the red humanw cell surface play an important role in increasing the values of Vd for Epo in comparison to its physiological distribution limited to extravascular space in the body.
Subscribe to free Drugs. Also, the difference in other pharmacokinetic parameters presented in Table 3 remained insignificant after adjustment. Anaemia in Balkan endemic nephropathy.